Maddie Meyer/Getty Images News
- Moderna (NASDAQ:MRNA) shares traded lower in the premarket on Wednesday after the Cambridge, Massachusetts-based biotech said it has voluntarily withdrawn its marketing application for its flu/COVID combination vaccine candidate, mRNA-1083.
- The COVID-19 vaccine maker had submitted the Biologics License Application (BLA) for